Prognostic factors for diffuse large B-cell lymphoma: clinical and biological factors in the rituximab era
Diffuse large B-cell Lymphoma (DLBCL) is a malignant lymphoma with a high incidence rate in adults. There are about 150,000 new DLBCL patients worldwide each year, accounting for 30-40% of the newly diagnosed non-Hodgkin's lymphoma (NHL) cases, while the incidence rate of the disease is 53.9% of NHL in China 1,2. DLBCL has not only a noticeable heterogeneity in clinicopathology, but also has diverse clinical characteristics. It is also complex and diverse in histomorphology, immunophenotype, biological behavior, and molecular genetics.
Source: Experimental Hematology - Category: Hematology Authors: Xiping Liang, Renzhi Hu, Qiying Li, Chaoyu Wang, Yao Liu Tags: Review Source Type: research
More News: Cancer & Oncology | China Health | Genetics | Hematology | Hodgkin's Disease | Lymphoma | Molecular Biology | Non-Hodgkin's Lymphoma | Rituxan